Protein type linked to Kawasaki disease

Article

Investigators set out to determine whether plasma levels of follistatin-like protein 1 (FSTL-1), which is produced by cardiac myocytes, correlate with Kawasaki disease (KD) and acquired coronary artery aneurysms (CAA), of which KD is a major cause.

Investigators set out to determine whether plasma levels of follistatin-like protein 1 (FSTL-1), which is produced by cardiac myocytes, correlate with Kawasaki disease (KD) and acquired coronary artery aneurysms (CAA), of which KD is a major cause.

Frozen plasma samples drawn from 48 children were analyzed at acute presentation of typical KD and at
2 weeks, 6 weeks, and 6 months later; 1 of these children developed CAA. Researchers also analyzed 6 additional acute samples from patients with KD in whom CAA were known to have developed subsequently, as well as plasma samples from 23 healthy children who served as controls.

Enzyme-linked immunosorbent assays showed that plasma FSTL-1 levels in children with acute KD were elevated compared with levels in control patients. Levels remained elevated at 2 weeks after disease onset, but by 6 weeks, levels in patients with KD and controls were not significantly different, and KD samples returned to control levels by 6 months.

Investigators also observed a positive correlation between FSTL-1 levels and height of fever in patients with KD and no aneurysms. They concluded that high levels of FSTL-1 might be a biomarker for development of CAA in KD (Gorelik M, et al. J Pediatr. 2012;161[1]:116-119).

Commentary

This observation may lead to increased understanding of the pathophysiology of coronary aneurysms after KD. Or, even better, maybe researchers will find a role for FSTL-1 in making the diagnosis, predicting prognosis, and even in preventive treatment in KD. -Michael Burke, MD

Recent Videos
David Turkewitz, MD
H. Westley Phillips, MD
David Turkewitz, MD
Rakesh Jain, MD, MPH
Rakesh Jain, MD, MPH
Paul Helmuth, MD
Brittany Bruggeman, MD
Octavio Ramilo
Melissa Fickey, MD
© 2024 MJH Life Sciences

All rights reserved.